Investment
Features
FeesSafety
Academy
More
Pluang+

Compare National Beverage Corp. (FIZZ) vs Stryker Corporation (SYK) Price & Performance

National Beverage Corp.Trade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

National Beverage Corp. vs Stryker Corporation — how do they compare? National Beverage Corp. trades at $32.1 (market cap $2.89B), while Stryker Corporation trades at $329.15 (market cap $121.31B). The key difference: Stryker Corporation is far larger — about 42× National Beverage Corp.'s market cap, and Stryker Corporation pays a 1.11% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.

FIZZSYK
Market Cap
$2.89B$121.31B
Sector
Consumer CyclicalTechnology
52-Week High
$47.69$403.53
52-Week Low
$30.85$282.58
Enterprise Value
$2.60B$133.07B
Dividend Yield
1.11%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

National Beverage Corp.

FIZZ trades at $32.09, up 3.78% on the day, but the stock faces bearish technical signals and mixed earnings results, with three of the last four quarters missing EPS estimates. The company maintains solid profitability with a 15.56% net income margin and a 34.03% ROE, while a recent special dividend of $3.25 per share reflects shareholder returns. However, revenue has stagnated around $1.2 billion annually, and analyst sentiment is cautious, with 50% of coverage recommending Sell.

The outlook for FIZZ is clouded by stalled growth and competitive pressures, particularly for its LaCroix brand. While valuation multiples like a P/E of 15.73 appear reasonable, the lack of revenue catalysts and bearish technical trends suggest limited near-term upside. Key risks include declining volumes and consumer weakness, requiring investors to weigh dividend returns against fundamental headwinds.

Stryker Corporation

Stryker (SYK) trades at $329.38, up 5.84% in the last session, yet technical indicators signal a bearish trend. The company reported a Q1 2026 earnings miss due to a temporary cyber disruption but maintained full-year guidance, with strong profitability margins and robust cash flow. Recent news highlights expansion of its Mako robotics platform, reinforcing its innovation-led growth strategy in the medical technology sector.

The investment outlook is positive based on strong fundamentals and analyst consensus, but near-term risks include competitive pressures and execution challenges. With a consensus price target of $388.44 representing ~18% upside, the stock offers value for long-term investors, though volatility may persist until Q2 earnings clarify the post-disruption recovery.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About National Beverage Corp.

National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.

Read more on FIZZ

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK